China's first single-table dual-drug HIV treatment drug Dovito® medical insurance prescription has been launched, leading the new trend of "simplified treatment"!

2022 Nian 1 Yue 4 days, GlaxoSmithKline ( GSK ) 's two-drug HIV regimens multi-Wei asked ^® (generic name: lamivudine more than raltegravir tablets) health insurance first party affiliated Beijing You An Hospital, Capital Medical University Landing

2022 Nian 1 Yue 4 days, GlaxoSmithKline ( GSK ) 's two-drug HIV regimens multi-Wei asked ^{® ®} (generic name: lamivudine more than raltegravir tablets) health insurance first party Capital Medical University, Beijing You The hospital landed

GlaxoSmithKline monolithic two-drug HIV treatment drugs more than Wei asked ^® China's first Medicare prescription landing

GlaxoSmithKline monolithic two-drug HIV treatment drugs more than Wei asked ^{® ®} China's first Medicare prescription landing

Multi-Wei asked ^® is the "China AIDS treatment guidelines ( 2021 edition)" first-line drugs recommended by a fixed dose of more than raltegravir ( 50 mg ) and lamivudine ( 300 mg ) composition

Multi-Wei asked ^{® ®} is the "China AIDS treatment guidelines ( 2021 edition)" first-line drugs recommended by a fixed dose of more than raltegravir ( 50 mg ) and lamivudine ( 300 mg ) composition

As of the end of 2020 , a total of 1.

Capital Medical University, Beijing You An Hospital Research Center for Infectious Diseases Clinical Professor Lord Ren Zhangtong said: " China's current HIV treatment has entered the ' troika ' phase, free medicine, drugs at their own expense, medical insurance drugs exist, each patient can choose the most suitable treatment

" Multi-Wei asked ^{® ®} from approved, listed on the Medicare floor to achieve a ' China speed '

references

1.

1.

2.

3, country / AIDS HIV Research Progress of Epidemiology , Chinese Center for Disease Control, https://baijiahao.
baidu.
com/s?id=1717561617758656559&wfr=spider&for=pc

in this message